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oncologic products within Latin America (LA) in comparison to a developed market 
(Canada). Methods: A panel of opinion leaders and policy-makers from Brazil, 
Colombia, Argentina, Mexico, and Canada was convened to understand current 
challenges in health care, patient access, and reimbursement of high-cost onco-
logic products with a focus on NSCLC. Results: In LA, patient access to biomarker 
testing in all cancers is limited, except for common biomarkers like HER2 in breast 
cancer. In Canada, there is no uniform coverage across provinces for diagnostic 
testing. In LA, there is an inconsistent and varied level of prioritization in public 
and private markets amongst various cancers (e.g. breast) for which access to high-
cost oncologic agents is more likely. Specifically, NSCLC is not prioritized because 
of its perceived association with smoking and “poor prognosis”. It is unlikely in LA 
for expensive medications to be included in the standard benefit packages, and 
the review process can be lengthy for those that are included. Some patients may 
get access to some medications through filing a judicial claim against the govern-
ment for individual drug cost reimbursement. Although various LA countries are 
witnessing evolution in some form, unlike in Canada, HTA does not have a substan-
tial influence on payer decision-making on drug coverage. There was a consensus 
for enrolling more patients in clinical trials, development of regional/local clinical 
guidelines, and generating real-world and cost-effectiveness evidence to potentially 
improve reimbursement and shorten time to access to medications. ConClusions: 
Access to high-cost oncologic medications could be potentially improved through 
increased patient participation in clinical trials, generation of relevant guidelines 
and robust cost-effectiveness and evidence-based analyses, and implementation 
of risk-sharing agreements requiring innovative cancer care models.
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objeCtivos: Estimar la utilización de servicios de salud para el tratamiento del 
cáncer de pulmón en centros especializados. MetodologíAs: Se realizó un estudio 
retrospectivo, con una muestra representativa de 100 historias clínicas de pacientes 
con ingreso por cáncer de pulmón en 2013 en tres hospitales. Se elaboró una base 
de datos con el registro de utilización de servicios antes del ingreso y durante el 
tratamiento en el hospital. ResultAdos: La edad promedio al ingreso fue 43 años. 
El 35% de los pacientes eran hombres, y el 65% eran mujeres. El 74% eran fumadores. 
Antes del ingreso, 11% de los pacientes recibió radioterapia, 9% quimioterapia y en el 
15% se realizó cirugía. El marcador tumoral EGFR fue reportado en una historia. En 
el 61% de las notas de ingreso, se indicó el resultado de la biopsia. Luego del ingreso, 
el peso del paciente fue reportado en el 41% de las historias, la talla en el 66%. En 
el 33% de las historias se registró el estadio del cáncer en la primera consulta. El 
promedio de consultas por paciente fue 6. El 2% de los pacientes requirió ingresos 
por emergencia. El 18% de los pacientes fue hospitalizado en el período de reporte. 
El marcador tumoral EGFR se reportó en 11% de las historias, en 38% los valores de 
LDH. En el período analizado, el 53% de los pacientes recibió quimioterapia y el 10% 
radioterapia. ConClusiones: De acuerdo con cifras oficiales, el cáncer de pulmón 
representó en 2012 el 14,83% de la mortalidad en Venezuela. El trabajo constituye 
el primero en la literatura venezolana para la estimación de servicios utilizados en 
el tratamiento respectivo. Los resultados son un aporte para la determinación de 
los costos involucrados, así como para la revisión de los estándares de atención en 
los servicios de salud.
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objeCtivos: Estimar la utilización de servicios de salud para el tratamiento del 
cáncer de estómago en centros especializados. MetodologíAs: Se realizó un 
estudio retrospectivo, con una muestra representativa de 100 historias clínicas 
de pacientes con ingreso por cáncer de estómago en 2013 en tres hospitales. Se 
elaboró una base de datos con el registro de utilización de servicios antes del 
ingreso y durante el tratamiento en el hospital. ResultAdos: La edad promedio 
al ingreso fue 48 años. El 51% de los pacientes eran hombres, y el 49% eran mujeres. 
Antes del ingreso al servicio de oncología, 3% de los pacientes recibió radiotera-
pia, 5% quimioterapia y en el 52% de los casos se realizó cirugía. No se registró la 
realización de marcadores tumorales (ALK, EGFR, BRAF, y PDL1). En el 64% de las 
notas de ingreso, se indicó el resultado de la biopsia. Luego del ingreso, el peso y 
la talla fueron reportados en el 67% de las historias. En el 28% de las historias se 
registró el estadio del cáncer en la primera consulta. El promedio de consultas 
por paciente fue 4. En el período analizado, el 32% de los pacientes fue hospitali-
zado, el 30% recibió quimioterapia y el 6% radioterapia. El 7% de los pacientes 
requirió ingresos por emergencia. No se reportaron marcadores tumorales durante 
el tratamiento en el hospital. En 32% de las historias se indicaron los valores de 
LDH. ConClusiones: De acuerdo con cifras oficiales, el cáncer de estómago rep-
resentó en 2012 el 16,64% de la mortalidad en Venezuela. El trabajo constituye el 
primero en la literatura venezolana para la estimación de servicios utilizados en 
el tratamiento respectivo. Los resultados son un aporte para la determinación de 
los costos involucrados, así como para la revisión de los estándares de atención 
en los servicios de salud.
be higher than the proportion expected by incidence statistics; this may be due to 
the indolent nature of FL and correspondingly high survival. FL was predominantly 
treated with Benda/Ritux and CVP R with some patients receiving CHOP R. WM was 
treated with CVP R, Benda/Ritux and Bort/Dexam +/- Ritux. MCL was treated with 
Benda/Ritux, Stem Cell Transplant, and CHOP R. DLBCL was treated with CHOP R. 
The other forms of NHL had various treatment regimens. ConClusions: The most 
prevalent NHL subtypes are FL and DLBCL. Treatment decisions for NHL are highly 
dependent on subtype, with indolent lymphomas being treated with regimens that 
are easier to tolerate, and aggressive lymphomas being treated predominately with 
CHOP R, an aggressive regimen that is hard to tolerate.
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objeCtives: Treatment of metastatic pancreatic cancer (MPC) remains a challenge 
for oncologists worldwide, since not many innovations were added lately. From 
1997 to 2011 (when the pivotal study on FOLFIRINOX was published), patients were 
essentially treated with gemcitabine. Recent publications show new options, such 
as OFF regimen. Nevertheless, there is a lack real world data showing how patients 
are actually treated. Our aim is to understand the treatment patterns for MPC in 
Brazil. Methods: MPC patients receiving any line of treatment during 2014 were 
eligible and selected from Evidências-Kantar Health administrative claims database 
(comprising 4 million lives insured by 46 different private health insurance com-
panies). After patient de-identification, data on treatments, number of cycles and 
demographics, were collected. The most reported treatments according to generic 
name were defined as patterns of care. Results: Sixty-three patients with MPC 
were identified at the database, 53 in first and 10 in second line treatment. Patient 
baseline characteristics were: average age 63.5 years (40 to 84), 66.72 kilos (45 to 
126kg), 1.65 meters of height (1.46 to 1.82m), and 1.71m2 body surface area (1.34 
to 2.3 m2). The most common regimen in first line was gemcitabine monotherapy 
(58.5%) followed by FOLFIRINOX (37.7%) and OFF (1.88%). In second line, OFF was 
the most prescribed regimen (80%), followed by gemcitabine monotherapy (10%) 
and FOLFORINOX (10%). Most patients in first-line received 3 cycles of treatment 
(43.4%), 32.1% received 6 cycles, 13,2% received 12 cycles and 11,3% received vari-
able length of treatment. Patients in second line received either 3 cycles (30%) or 
6 cycles (70%). ConClusions: Despite the higher overall survival demonstrated 
by FOLFIRINOX study, the first option for first-line treatment of MPC patients is 
still gemcitabine. However, in second line the trend appears to be shifting towards 
OFF regimen.
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objeCtives: There is limited data on the prevalence, rate of mutations, and pat-
terns of treatment in a “real-world” setting in Brazil. The aim of this retrospective 
observational study was to evaluate the above-mentioned aspects from the pri-
vate health system’s perspective in the country. Methods: Data from 44 HMOs 
on all patients with metastatic NSCLC receiving any line of treatment between 
September 2013 - September 2014 using Evidências-Kantar Health private mar-
ket administrative claims database was analyzed. After patient de-identification, 
information on demographics, diagnosis, and treatment regimens and duration 
was collected. Prevalence of patients in each treatment line was calculated by the 
number of existing cases of a disease by the total population with lung cancer at one 
year. Results: We identified 273 lung cancer patients of which 182 patients (66.7%) 
had metastatic NSCLC, and were thus eligible for analysis. The most frequent histol-
ogy type was adenocarcinoma (71%) followed by squamous cell carcinoma (12%). 
The majority (81%) was not tested for any mutation. Among the tested patients 
(n= 35), 1 patient was ALK+ and 17 were EGFR+. The only ALK+ patient received a 
second line treatment with carboplatin+pemetrexed. Of the 17 patients with EGFR 
mutation, 52.9% used erlotinib and 23.5% gefitinib. Patient baseline characteristics 
of analyzed 182 patients were: average age of 64.3 years, 67.2 kilos, 1.6 m height, and 
1.74m2 body surface area. Nineteen treatment regimens were identified and most 
patients received 3 cycles of treatment. The most common regimens in first, second, 
and third-line treatments were carboplatin+pemetrexed (31%), docetaxel mono-
therapy (57.1%), and erlotinib (80%), respectively. The proportion of patients with 
NSCLC that undergo first, second, third, fourth, and fifth-line treatments in one year 
was 46.2/100, 20.5/100, 3.7/100, 0.7/100, and 1.1/100, respectively. ConClusions: 
Mutation testing was very low, representing a significant unmet need, as patients 
with mutations may not be receiving appropriate targeted treatment in first-line.
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objeCtives: To understand key market access issues pertaining to reimburse-
ment, HTA policies, guidelines, and ways to improve patient access for innovative 
